BriaCell Partners with Caris Life Sciences® to Expand Patient Outreach and Molecular Profiling
September 14 2022 - 9:20AM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:
BCT) (“BriaCell” or the “Company”), a clinical-stage
biotechnology company specializing in targeted immunotherapies for
cancer, announces that it has signed an agreement with Caris Life
Sciences® (Caris), a leading molecular science and technology
company actively developing and delivering innovative solutions to
revolutionize healthcare.
“Our goal is to develop immunotherapies that are
personalized for each patient, and Caris’ extensive library of
clinical data, cutting-edge biomarker technology, and expertise
will be invaluable in achieving our objectives,” stated Dr.
Giuseppe Del Priore, BriaCell’s Chief Medical Officer. “We expect
Caris’ unique platform to help us identify patients who do not
respond to existing treatments and are more likely to benefit from
our immunotherapy treatments.”
Under the terms of the agreement, Caris will
help BriaCell with efficient patient identification, accelerating
enrollment for its current Phase I/II clinical trial in advanced
metastatic breast cancer of certain genetically defined subgroups.
The partnership between BriaCell and Caris leverages Caris’
Right-In-Time (RIT) Clinical Trial Network, a group of over 495
oncology sites that are able to quickly identify and enroll
eligible patients in biomarker-directed clinical trials. This
service offers patients and physicians access to the most
cutting-edge precision medicine in development. Additionally,
through Caris’ comprehensive molecular profiling (Whole Exome and
Whole Transcriptome Sequencing), Caris will perform tumor profiling
for the patients enrolled in the clinical trial.
About BriaCell Therapeutics
Corp.
BriaCell is an immuno-oncology-focused
biotechnology company developing targeted and effective approaches
for the management of cancer. More information is available at
https://briacell.com/.
About Caris Life Sciences
Caris Life Sciences® (Caris) is the leading
molecular science and technology company actively developing and
delivering innovative solutions to revolutionize healthcare and
improve patient outcomes. Through comprehensive molecular profiling
(Whole Exome and Whole Transcriptome Sequencing) and the
application of advanced artificial intelligence (AI) and machine
learning algorithms, Caris has created the large-scale
clinico-genomic database and cognitive computing needed to analyze
and unravel the molecular complexity of disease. This information
provides an unmatched resource and the ideal path forward to
conduct the basic, fundamental research to accelerate discovery for
detection, diagnosis, monitoring, therapy selection and drug
development to improve the human condition.
With a primary focus on cancer, Caris’ suite of
market-leading molecular profiling offerings assesses DNA, RNA and
proteins to reveal a molecular blueprint that helps patients,
physicians and researchers better detect, diagnose and treat
patients. Caris’ latest advancement is a blood-based, circulating
nucleic acids sequencing (cNAS) assay that combines comprehensive
molecular analysis (Whole Exome and Whole Transcriptome Sequencing
from blood) and serial monitoring – making it the most powerful
liquid biopsy assay ever developed.
Headquartered in Irving, Texas, Caris has
offices in Phoenix, New York, Denver, Tokyo, Japan and Basel,
Switzerland. Caris provides services throughout the U.S., Europe,
Asia and other international markets. To learn more, please
visit CarisLifeSciences.com or follow Caris on Twitter
(@CarisLS).
Safe Harbor
This press release contains “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” “will,” “would,” or the negative of
these words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements are based on BriaCell’s current expectations and are
subject to inherent uncertainties, risks and assumptions that are
difficult to predict. Further, certain forward-looking statements
are based on assumptions as to future events that may not prove to
be accurate. These and other risks and uncertainties are described
more fully under the heading “Risks and Uncertainties” in the
Company's most recent Management’s Discussion and Analysis, under
the heading "Risk Factors" in the Company's most recent Annual
Information Form, and under “Risks and Uncertainties” in the
Company's other filings with the Canadian securities regulatory
authorities and the U.S. Securities and Exchange Commission, all of
which are available under the Company's profiles on SEDAR at
www.sedar.com and on EDGAR at www.sec.gov.
Forward-looking statements contained in this announcement are made
as of this date, and BriaCell Therapeutics Corp. undertakes no duty
to update such information except as required under applicable
law.
Neither Toronto Stock Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Toronto Stock Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Contact Information
Company Contact:William V.
Williams, MDPresident &
CEO1-888-485-6340info@briacell.com
Media Relations:Jules
AbrahamDirector of Public RelationsCORE
IR917-885-7378julesa@coreir.com
Investor Relations Contact:CORE
IRinvestors@briacell.com
Caris Life Sciences Media
Contact: Lisa Burgnercorpcomm@carisls.com214-294-5606
BriaCell Therapeutics (NASDAQ:BCTX)
Historical Stock Chart
From Jul 2024 to Aug 2024
BriaCell Therapeutics (NASDAQ:BCTX)
Historical Stock Chart
From Aug 2023 to Aug 2024